MONDAY, APRIL 8 - TUESDAY, APRIL 9
DAY 1: 8:30 AM - 12:30 PM | DAY 2: 8:30 AM - 5:25 PM (Tremont)
TS12A: INTRODUCTION TO BIOPROCESSING
DAY 1: MONDAY
8:30 am - 12:30 pm Seminar Sessions
2:20 - 3:20 pm Problem Solving Roundtables
4:00 - 5:40 pm Plenary Session
5:40 - 7:15 pm Welcome Reception
DAY 2: TUESDAY
8:30 am - 5:25 pm Seminar Sessions
12:30 - 1:00 pm Lunch Provided
Exhibit Hall Refreshment Breaks also provided.
Instructors:
Sheila G. Magil, Ph.D., Principal Consultant, BioProcess Technology Consultants, Inc.
Frank J. Riske, Ph.D., Senior Consultant, BioProcess Technology Consultants, Inc.
CHI’s Introduction to Bioprocessing training seminar offers a comprehensive survey of the steps needed to produce today’s complex biopharmaceuticals, from early development through commercial. The seminar begins with a brief introduction to biologic drugs and the aspects of protein science that drive the intricate progression of analytical and process steps that follows. We then step through the stages of bioprocessing, beginning with the development of cell lines and ending at scaling up for commercial production. The seminar also explores emerging process technologies, facility design considerations and the regulatory and quality standards that govern our industry throughout development. The important roles of analytical methods at all stages of development as well as formulation and stability assessments in developing and gaining approval for a biopharmaceutical are also examined. This 1.5-day class is directed to attendees working in any aspect of industry, including scientific, technical, business, marketing or support functions, who would benefit from a detailed overview of this field.
Topics include:
An Introduction to Biopharmaceuticals and Bioprocessing
Analytical Methods for the Characterization and Release of Biotherapeutics
- Structure-function
- Bioassay
- Higher-order structure
- Phase-appropriate methods
Quality Systems
- Overview
- Quality by Design (QbD)
- Phase-appropriate quality systems
The Science and Technologies of Bioprocess Unit Operations
Cell Line and Upstream Development
- Expression system selection and development
- Cell banking: Master and working cell bank generation and testing
- Cell culture and fermentation development
- Continuous feed/perfusion/fed batch
- Single use
Recovery and Downstream Development
- Affinity capture
- Platform processes
- Purification development strategies
- Polishing and final processing
- Viral clearance validation
Drug Product Development
- Liquid, lyophilized and other forms
- Formulation development
- Device and packaging considerations
- Combination products
Scaling Up Drug Substance
- Considerations in scaling up
- Engineering and first cGMP runs
- Facility considerations
- Tech transfer
Comparability during Scale-Up and after Process Changes
Ready for Late-Stage Development
- Process qualification
- Facility concerns
- Equipment qualification
Ready for Commercial
- What is needed
- Supply chain considerations
- BLAs/NDAs
Instructor Biographies:
Sheila G. Magil, Ph.D., Principal Consultant, BioProcess Technology Consultants, Inc.
Sheila Magil has over 20 years of experience in quality and analytical method development for biologics, peptides and small molecules. Her expertise includes quality assurance, protein and peptide biochemistry and analytical development. She was formerly Senior Manager of Analytical Development and Quality Control at Biomeasure, Inc., and previously held positions at Waratah Pharma, Alkermes, Bion and HHMI at Massachusetts General Hospital. Dr. Magil has implemented quality systems and has managed external analytical and QC activities for multiple biopharmaceutical products. Dr. Magil holds a Ph.D. in Biochemistry from the University of Minnesota.
Frank J. Riske, Ph.D., Senior Consultant, BioProcess Technology Consultants
Frank J Riske, Ph.D., Senior Consultant at BioProcess Technology Consultants has over 25 years of experience in the biopharmaceutical industry. Prior to joining BioProcess Technology Consultants, Dr. Riske was Senior Director in the Late Phase Process Development Group at Genzyme, a Sanofi company. Before Genzyme, Dr. Riske held positions at Epic Therapeutics, Repligen and Hoffmann-LaRoche. Dr. Riske has extensive experience in the development of downstream processes for cytokines, proteins and virus from plasma, E coli, Pichia and mammalian systems and in the development and manufacture of novel drug delivery systems. Dr. Riske received his B.S. in Biology from Fairfield University, Ph.D. in Biochemistry and Microbiology from Rutgers University and completed a post-doctoral position at Hoffmann-LaRoche.
What is a Training Seminar?
Each Training Seminar offers 1.5 Days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.
Each person registered specifically for the training seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the seminar, but after these have been distributed no additional books will be available.
Though CHI encourages track and symposia hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because Seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and NOT engaging in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.
